You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 19, 2025

Claims for Patent: 12,071,423

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 12,071,423

Title:	Processes and intermediate for the large-scale preparation of 2,4,6-trifluoro-N-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-benzamide hemisuccinate, and preparation of 2,4,6-trifluoro-N-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-benzamide acetate
Abstract:	The embodiments of present invention provide processes for the large-scale preparation of 2,4,6-trifluoro-N-[6-(1-methylpiperidine-4-carbonyl)-2-pyridyl]benzamide hemisuccinate, and formulations and product forms, such as tablets, made by these processes. Additionally, embodiments of the present invention provide tablets including 25 mg, 50 mg, 100 mg, or 200 mg free base equivalent of 2,4,6-trifluoro-N-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-benzamide hemisuccinate.
Inventor(s):	Aktham Aburub, David Andrew Coates, Scott Alan Frank, Mark Steven Kerr, Roger Ryan Rothhaar, Radhe Krishan Vaid
Assignee:	Eli Lilly and Co
Application Number:	US18/134,747
Patent Claims:	1. An immediate-release tablet, wherein the tablet comprises: (a) from 50 mg to 100 mg free base equivalent of 2,4,6-trifluoro-N-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-benzamide hemisuccinate; (b) from 30.86 mg to 61.71 mg of microcrystalline cellulose; (c) from 7.5 mg to 15.00 mg of pregelatinized starch; (d) from 0.56 mg to 1.12 mg of sodium lauryl sulfate; (e) from 5.63 mg to 40.53 mg of croscarmellose sodium; (f) from 2.25 mg to 4.50 mg of magnesium stearate; and (g) from 3.519 mg to 7.035 mg of the film coating. 2. The immediate release tablet of claim 1, wherein the tablet comprises: (a) 50 mg free base equivalent of 2,4,6-trifluoro-N-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-benzamide hemisuccinate; (b) 30.86 mg of microcrystalline cellulose; (c) 7.5 mg of pregelatinized starch; (d) 0.56 mg of sodium lauryl sulfate; (e) 13.51 mg of croscarmellose sodium; (f) 2.25 mg of magnesium stearate; and (g) 3.519 mg of the film coating. 3. The immediate-release tablet of claim 1, wherein the tablet comprises: (a) 100 mg free base equivalent of 2,4,6-trifluoro-N-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-benzamide hemisuccinate; (b) 61.71 mg of microcrystalline cellulose; (c) 15.00 mg of pregelatinized starch; (d) 1.12 mg of sodium lauryl sulfate; (e) 40.53 mg of croscarmellose sodium; (f) 4.50 mg of magnesium stearate; and (g) 7.035 mg of the film coating. 4. The immediate-release tablet of claim 1, wherein the tablet is provided in a unit-dose blister.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.